Selected research
Market Structure
Global Mesalazine Enteric Coated Tablets Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Mesalazine Enteric Coated Tablets market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Mesalazine Enteric Coated Tablets is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Mesalazine Enteric Coated Tablets is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Mesalazine Enteric Coated Tablets is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Mesalazine Enteric Coated Tablets is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Mesalazine Enteric Coated Tablets include CR Sanjiu, Huahai Pharmaceuticals, UCB Pharma, Sun Pharmaceutical Industries Ltd., Fosun Pharma, DSM Pharmaceuticals, Dr. Falk Pharma GmbH, Astellas Pharma Inc. and AbbVie Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Mesalazine Enteric Coated Tablets market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Mesalazine Enteric Coated Tablets and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Mesalazine Enteric Coated Tablets sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Mesalazine Enteric Coated Tablets market size, projected growth trends, production technologies, key applications, and end-use industries.
Mesalazine Enteric Coated Tablets Segment by Company
CR Sanjiu
Huahai Pharmaceuticals
UCB Pharma
Sun Pharmaceutical Industries Ltd.
Fosun Pharma
DSM Pharmaceuticals
Dr. Falk Pharma GmbH
Astellas Pharma Inc.
AbbVie Inc.
Mesalazine Enteric Coated Tablets Segment by Type
0.25g
0.5g
1g
Mesalazine Enteric Coated Tablets Segment by Application
Hospital
Clinic
Others
Mesalazine Enteric Coated Tablets Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Mesalazine Enteric Coated Tablets market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Mesalazine Enteric Coated Tablets and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Mesalazine Enteric Coated Tablets.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Mesalazine Enteric Coated Tablets market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Mesalazine Enteric Coated Tablets manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Mesalazine Enteric Coated Tablets in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Mesalazine Enteric Coated Tablets in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- 0.25g
- 0.5g
- 1g
Applications
- Hospital
- Clinic
- Others
Companies covered
- CR Sanjiu
- Huahai Pharmaceuticals
- UCB Pharma
- Sun Pharmaceutical Industries Ltd.
- Fosun Pharma
- DSM Pharmaceuticals
- Dr. Falk Pharma GmbH
- Astellas Pharma Inc.
- AbbVie Inc.
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Mesalazine Enteric Coated Tablets Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Mesalazine Enteric Coated Tablets Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Mesalazine Enteric Coated Tablets Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Mesalazine Enteric Coated Tablets Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Mesalazine Enteric Coated Tablets Market Dynamics
- 2.1 Mesalazine Enteric Coated Tablets Industry Trends
- 2.2 Mesalazine Enteric Coated Tablets Industry Drivers
- 2.3 Mesalazine Enteric Coated Tablets Industry Opportunities and Challenges
- 2.4 Mesalazine Enteric Coated Tablets Industry Restraints
3 Mesalazine Enteric Coated Tablets Market by Manufacturers
- 3.1 Global Mesalazine Enteric Coated Tablets Revenue by Manufacturers (2021-2026)
- 3.2 Global Mesalazine Enteric Coated Tablets Sales by Manufacturers (2021-2026)
- 3.3 Global Mesalazine Enteric Coated Tablets Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Mesalazine Enteric Coated Tablets Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Mesalazine Enteric Coated Tablets Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Mesalazine Enteric Coated Tablets Manufacturers, Product Type & Application
- 3.7 Global Mesalazine Enteric Coated Tablets Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Mesalazine Enteric Coated Tablets Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Mesalazine Enteric Coated Tablets Players Market Share by Revenue in 2025
- 3.8.3 2025 Mesalazine Enteric Coated Tablets Tier 1, Tier 2, and Tier 3
4 Mesalazine Enteric Coated Tablets Market by Type
- 4.1 Mesalazine Enteric Coated Tablets Type Introduction
- 4.1.1 0.25g
- 4.1.2 0.5g
- 4.1.3 1g
- 4.2 Global Mesalazine Enteric Coated Tablets Sales by Type
- 4.2.1 Global Mesalazine Enteric Coated Tablets Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Mesalazine Enteric Coated Tablets Sales by Type (2021-2032)
- 4.2.3 Global Mesalazine Enteric Coated Tablets Sales Market Share by Type (2021-2032)
- 4.3 Global Mesalazine Enteric Coated Tablets Revenue by Type
- 4.3.1 Global Mesalazine Enteric Coated Tablets Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Mesalazine Enteric Coated Tablets Revenue by Type (2021-2032)
- 4.3.3 Global Mesalazine Enteric Coated Tablets Revenue Market Share by Type (2021-2032)
5 Mesalazine Enteric Coated Tablets Market by Application
- 5.1 Mesalazine Enteric Coated Tablets Application Introduction
- 5.1.1 Hospital
- 5.1.2 Clinic
- 5.1.3 Others
- 5.2 Global Mesalazine Enteric Coated Tablets Sales by Application
- 5.2.1 Global Mesalazine Enteric Coated Tablets Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Mesalazine Enteric Coated Tablets Sales by Application (2021-2032)
- 5.2.3 Global Mesalazine Enteric Coated Tablets Sales Market Share by Application (2021-2032)
- 5.3 Global Mesalazine Enteric Coated Tablets Revenue by Application
- 5.3.1 Global Mesalazine Enteric Coated Tablets Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Mesalazine Enteric Coated Tablets Revenue by Application (2021-2032)
- 5.3.3 Global Mesalazine Enteric Coated Tablets Revenue Market Share by Application (2021-2032)
6 Global Mesalazine Enteric Coated Tablets Sales by Region
- 6.1 Global Mesalazine Enteric Coated Tablets Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Mesalazine Enteric Coated Tablets Sales by Region (2021-2032)
- 6.2.1 Global Mesalazine Enteric Coated Tablets Sales by Region (2021-2026)
- 6.2.2 Global Mesalazine Enteric Coated Tablets Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Mesalazine Enteric Coated Tablets Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Mesalazine Enteric Coated Tablets Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Mesalazine Enteric Coated Tablets Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Mesalazine Enteric Coated Tablets Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Mesalazine Enteric Coated Tablets Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Mesalazine Enteric Coated Tablets Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Mesalazine Enteric Coated Tablets Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Mesalazine Enteric Coated Tablets Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Mesalazine Enteric Coated Tablets Revenue by Region
- 7.1 Global Mesalazine Enteric Coated Tablets Revenue by Region
- 7.1.1 Global Mesalazine Enteric Coated Tablets Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Mesalazine Enteric Coated Tablets Revenue by Region (2021-2026)
- 7.1.3 Global Mesalazine Enteric Coated Tablets Revenue by Region (2027-2032)
- 7.1.4 Global Mesalazine Enteric Coated Tablets Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Mesalazine Enteric Coated Tablets Revenue (2021-2032)
- 7.2.2 North America Mesalazine Enteric Coated Tablets Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Mesalazine Enteric Coated Tablets Revenue (2021-2032)
- 7.3.2 Europe Mesalazine Enteric Coated Tablets Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Mesalazine Enteric Coated Tablets Revenue (2021-2032)
- 7.4.2 Asia-Pacific Mesalazine Enteric Coated Tablets Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Mesalazine Enteric Coated Tablets Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Mesalazine Enteric Coated Tablets Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 CR Sanjiu
- 8.1.1 CR Sanjiu Company Information
- 8.1.2 CR Sanjiu Business Overview
- 8.1.3 CR Sanjiu Mesalazine Enteric Coated Tablets Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 CR Sanjiu Mesalazine Enteric Coated Tablets Product Portfolio
- 8.1.5 CR Sanjiu Recent Developments
- 8.2 Huahai Pharmaceuticals
- 8.2.1 Huahai Pharmaceuticals Company Information
- 8.2.2 Huahai Pharmaceuticals Business Overview
- 8.2.3 Huahai Pharmaceuticals Mesalazine Enteric Coated Tablets Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Huahai Pharmaceuticals Mesalazine Enteric Coated Tablets Product Portfolio
- 8.2.5 Huahai Pharmaceuticals Recent Developments
- 8.3 UCB Pharma
- 8.3.1 UCB Pharma Company Information
- 8.3.2 UCB Pharma Business Overview
- 8.3.3 UCB Pharma Mesalazine Enteric Coated Tablets Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 UCB Pharma Mesalazine Enteric Coated Tablets Product Portfolio
- 8.3.5 UCB Pharma Recent Developments
- 8.4 Sun Pharmaceutical Industries Ltd.
- 8.4.1 Sun Pharmaceutical Industries Ltd. Company Information
- 8.4.2 Sun Pharmaceutical Industries Ltd. Business Overview
- 8.4.3 Sun Pharmaceutical Industries Ltd. Mesalazine Enteric Coated Tablets Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Sun Pharmaceutical Industries Ltd. Mesalazine Enteric Coated Tablets Product Portfolio
- 8.4.5 Sun Pharmaceutical Industries Ltd. Recent Developments
- 8.5 Fosun Pharma
- 8.5.1 Fosun Pharma Company Information
- 8.5.2 Fosun Pharma Business Overview
- 8.5.3 Fosun Pharma Mesalazine Enteric Coated Tablets Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Fosun Pharma Mesalazine Enteric Coated Tablets Product Portfolio
- 8.5.5 Fosun Pharma Recent Developments
- 8.6 DSM Pharmaceuticals
- 8.6.1 DSM Pharmaceuticals Company Information
- 8.6.2 DSM Pharmaceuticals Business Overview
- 8.6.3 DSM Pharmaceuticals Mesalazine Enteric Coated Tablets Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 DSM Pharmaceuticals Mesalazine Enteric Coated Tablets Product Portfolio
- 8.6.5 DSM Pharmaceuticals Recent Developments
- 8.7 Dr. Falk Pharma GmbH
- 8.7.1 Dr. Falk Pharma GmbH Company Information
- 8.7.2 Dr. Falk Pharma GmbH Business Overview
- 8.7.3 Dr. Falk Pharma GmbH Mesalazine Enteric Coated Tablets Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Dr. Falk Pharma GmbH Mesalazine Enteric Coated Tablets Product Portfolio
- 8.7.5 Dr. Falk Pharma GmbH Recent Developments
- 8.8 Astellas Pharma Inc.
- 8.8.1 Astellas Pharma Inc. Company Information
- 8.8.2 Astellas Pharma Inc. Business Overview
- 8.8.3 Astellas Pharma Inc. Mesalazine Enteric Coated Tablets Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 Astellas Pharma Inc. Mesalazine Enteric Coated Tablets Product Portfolio
- 8.8.5 Astellas Pharma Inc. Recent Developments
- 8.9 AbbVie Inc.
- 8.9.1 AbbVie Inc. Company Information
- 8.9.2 AbbVie Inc. Business Overview
- 8.9.3 AbbVie Inc. Mesalazine Enteric Coated Tablets Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 AbbVie Inc. Mesalazine Enteric Coated Tablets Product Portfolio
- 8.9.5 AbbVie Inc. Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Mesalazine Enteric Coated Tablets Value Chain Analysis
- 9.1.1 Mesalazine Enteric Coated Tablets Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Mesalazine Enteric Coated Tablets Production Mode & Process
- 9.2 Mesalazine Enteric Coated Tablets Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Mesalazine Enteric Coated Tablets Distributors
- 9.2.3 Mesalazine Enteric Coated Tablets Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst